Efficient human interferon-α gene transfer to neuroendocrine tumor cells with long-term and stable expression

Neuroendocrinology

Volumn 82, Issue 5-6, 2006, Pages 264-273

  Liu, Minghui ^a   Kilarski, Witold W ^a   Gerwins, Pär ^a   Öberg, Kjell ^a   Zhou, Yinghua ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; BON cells; Interferon ; Mice; Molecular neuroendocrinology; Neuroendocrine tumors

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CELL ADHESION; CELL BASED GENE THERAPY; CELL LINE; CHORIOALLANTOIS; CONTROLLED STUDY; DNA VECTOR; GENE TRANSFER; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; WILD TYPE;

ACTINS; ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; EIF-2 KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; RECOMBINANT PROTEINS; SWINE; TIME FACTORS;

EID: 33744479169     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092862     Document Type: Article

References (32)

1. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781.
2. Tagliaferri P, Caraglia M, Budillon A, et al: New pharmacokinetic and pharmacodynamic tools for interferon-α treatment of human cancer. Cancer Immunol Immunother 2005;54:1-10.
3. Pfeffer LM, Dinarello CA, Herberman RB, et al: Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-2499.
4. Bauer JA, Morrison BH, Grane RW, et al: IFN-α2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res 2003;23:3-10.
5. Streck CJ, Zhang Y, Miyamoto R, et al: Restriction of neuroblastoma angiogenesis and growth by interferon-α/β. Surgery 2004;136:183-189.
6. Von Marschall Z, Scholz A, Cramer T, et al: Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448.
7. De Bouard S, Guillamo JS, Christov C, et al: Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-α, angiostatin, or endostatin. Hum Gene Ther 2003;14:883-895.
8. Rosewicz S, Detjen K, Scholz A, von Marschall Z: Interferon-α: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(suppl 1):85-93.
9. Hatanaka K, Suzuki K, Miura Y, et al: Interferon-α and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004;6:1139-1148.
10. Luo Y, Chen X, Han R, O'Donnell MA: Recombinant bacille Calmette-Guérin expressing human interferon-α2b demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264-270.
11. Albini A, Marchisone C, Del Grosso F, et al: Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000;156:1381-1393.
12. Evers BM, Iskizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393-406.
13. Lundqvist M, Mark J, Funa K, et al: Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. Eur J Cancer 1991;27:1663-1668.
14. Zhou Y, Gobl A, Wang S, et al: Expression of p68 protein kinase and its prognostic significance during IFN-α therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046-2052.
15. Oki N, Matsuo H, Nakago S, et al: Effects of 3,5,3′- triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab 2004;89:5213-5221.
16. Zhou Y, Wang S, Gobl A, Oberg K: The interferon-α regulation of interferon regulatory factor (IRF)-1 and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 2000;11:707-714.
17. Kilarski WW, Jura N, Gerwins P: Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res 2003;291:70-82.
18. Liu M, Imam H, Oberg K, Zhou Y: Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. Neuroendocrinology 2005;82:1-10.
19. Hsu LC, Park JM, Zhang K, et al: The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004;428:341-345.
20. Donze O, Deng J, Curran J, et al: The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 2004;23:564-571.
21. McCarty MF, Bielenberg D, Donawho C, et al: Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002;19:609-615.
22. Brack SS, Dinkelborg LM, Neri D: Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging 2004;31:1327-1341.
23. Rege TA, Fears CY, Gladson CL: Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neurooncology 2005;7:106-121.
24. Kubis N, Levy BI: Understanding angiogenesis: a clue for understanding vascular malformations. J Neuroradiol 2004;31:365-368.
25. Behrens J, Frixen U, Schipper J, et al: Cell adhesion in invasion and metastasis. Semin Cell Biol 1992;3:169-178.
26. Van Roy F, Mareel M: Tumour invasion: effects of cell adhesion and motility. Trends Cell Biol 1992;2:163-169.
27. Heino J: Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996;65:717-722.
28. Solorzano CC, Hwang R, Baker CH, et al: Administration of optimal biological dose and schedule of interferon α combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003;9:1858-1867.
29. Vikman S, Essand M, Cunningham JL, et al: Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005;44:32-40.
30. Lindner M, Schirrmacher V: Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur J Clin Invest 2002;32:207-217.
31. Tsugawa T, Kuwashima N, Sato H, et al: Sequential delivery of interferon-α gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 2004;11: 1551-1558.
32. Liu Y, Saxena A, Zheng C, et al: Combined α tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J Gene Med 2004;6:857-868.